United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
541.51
+1.48 (0.27%)
Oct 15, 2026, 4:00 PM EDT - Market closed
United Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, United Therapeutics stock has a consensus rating of "Buy" and an average price target of $656.93. The average 1-year stock price forecast is 21.31% higher than the current stock price, while the lowest is $368 (-32.04%) and the highest is $728 (+34.44%).
Price Target: $656.93 (+21.31%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 8 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 15 | 15 | 15 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Sell Maintains $321 → $368 | Sell | Maintains | $321 → $368 | -32.04% | Oct 15, 2026 |
| UBS | UBS | Buy Maintains $725 | Buy | Maintains | $725 | +33.88% | Oct 14, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $685 | Buy | Reiterates | $685 | +26.50% | Oct 12, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Reiterates $559 | Hold | Reiterates | $559 | +3.23% | Oct 9, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $687 → $710 | Buy | Maintains | $687 → $710 | +31.11% | Oct 9, 2026 |
Financial Forecast
Revenue This Year
3.19B
from 3.18B
Increased by 0.16%
Revenue Next Year
3.61B
from 3.19B
Increased by 13.34%
EPS This Year
27.37
from 27.86
Decreased by -1.74%
EPS Next Year
34.68
from 27.37
Increased by 26.68%
EPS and Forward PE are based on non-GAAP adjusted numbers.